Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 1998

View Archived Issues

Company Profile: Millennium

Clinical development of LM-AS-013 advances at Green Cross

Inhibitors of the production or release of sCD23, TNF

Dopamine D4 receptor antagonists for imaging and therapy disclosed by Janssen

New excitatory amino acid antagonists in development at Pfizer

Meiji Seika describes 5-HT3 partial agonists for GI disorders

Triangle reports results from phase I/II FTC trial

Tsumura team reveals semisynthetic huperzine derivatives

More new agents for influenza from Lilly

PMPA reduces viral load in phase I/II

Potent, orally active inhibitor of kynurenine 3-hydroxylase discovered at Roche

Diphenylalkylamine derivative with cardioprotective properties characterized

ArQule and CuraGen establish broad drug discovery collaboration

Comparative trial of intracavernous alprostadil and MUSE for ED

Swiss Remune trials initiated

Long-term efficacy of epoprostenol for primary pulmonary hypertension

Optison imaging agent launched in U.S.

FDA advisory committee recommends Integrilin approval

Hybridon antitumor antisense compound enters clinical trials

Folic acid therapy and cardiovascular risk reduction

Anesta signs European marketing agreement for Actiq

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...